<DOC>
	<DOC>NCT00143130</DOC>
	<brief_summary>To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.</brief_summary>
	<brief_title>Pregabalin In Partial Seizures Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>met the inclusion/exclusion criteria for A0081005 have completed the 21week study and have shown a significant clinical response and wish to continue treatment Having a treatable cause of seizure. Having a progressive neurological or systemic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>phase 4, open label, seizures, epilepsy, add-on therapy, pregabalin, lyrica</keyword>
</DOC>